End-to-end platform for DUB-focused drug discovery and development

Our specialised drug discovery platform and long-standing expertise are empowering scientists to develop DUB inhibitors, DUB-targeting PROTACs, and DUBTACs into exciting new medicines

Ubiquigent™ has the assays, expertise, and capabilities to drive forward every step in the drug discovery workflow for DUB-focused therapeutic applications, from targeting DUBs as the drug target to harnessing them for the modulation or stabilisation of a given disease protein.

You can access any part of our platform to support your DUB-focused programmes.

We can evaluate your compounds in our existing assays and develop new assays on your behalf.

Studies can be conducted on a project-by-project basis or as part of larger FTE-based agreements.

You can find us on Scientist.com and Science Exchange, or we can work with you under one of our research agreements.

To explore how our services can help your programmes, contact us at services@ubiquigent.com.

Harness Ubiquigent's platform for the discovery and development of DUB inhibitors and DUB-targeting PROTACs

Scroll to view more →

Harness Ubiquigent's platform for the development of DUBTACS

Scroll to view more →

Suite of comprehensive biochemical and cellular assays

DUBprofiler

Widely cited, comprehensive and flexible profiling assay to characterise novel DUB-binding ligands to establish their potency and selectivity

DUBprofiler-Cell and DUBprofiler-Tissue

Flexible assays to determine target engagement and selectivity of DUB inhibitors in cell lysates, cell cultures, or tissue samples

PROTEOMEprofiler

Mass spectrometry-based assay that rapidly profiles the entire proteome to identify and validate DUB targets in disease and determine the mechanism of action for therapeutics targeting the UPS

REDOXprofiler

Critical counter-screening assay that separates false positives from genuine hits

DUBmechanism

Customised assays to investigate the mechanism of action of novel DUB targeting compounds

UBISITEprofiler

Unique ubiquitinomics assay for the comprehensive, unambiguous, and unbiased analysis of ubiquitination sites across the full proteome

DUBseeker

Comprehensive set of assays to identify the most appropriate DUB partner for a given target protein to drive the development of DUBTACs

DUBatlas

Proprietary toolkit for mapping the active DUBome in diseased vs non-diseased human or animal tissues, cells, or subcellular compartments

DUBscan

The generation of physiologically ubiquitinated target proteins and their *in vitro* deubiquitination using a panel of DUBs

DUBselect

Proximity profiling assay to generate cell-based proof-of-principle that induced proximity with a given DUB leads to stabilisation of a target protein and the desired phenotype

DUBbinder

Assay to identify novel compounds that bind selected DUBs

Custom Assay Development

Bespoke assays to screen compounds against exciting new DUB targets as they continue to emerge across a wide range of human diseases

Our end-to-end platform is driving the discovery and development of DUB inhibitors, DUB-targeting PROTACs, and DUBTACs